Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.82 – $2.14
Volume6,980
Market cap$1M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$945.46K
Price / earnings
—
Price / book
0.41×
Price / sales
472.73×
EV / sales
-3,127.77×
EV / EBITDA
1.24×
Profitability
Earnings per share
-$36.40
Return on assets
-92.53%
Return on equity
-755.28%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.18×
Current ratio
3.72×
Quick ratio
3.72×
Cash ratio
2.73×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.52M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NXTS, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Revenue
$0
$0
Cost of revenue
$0
$0
Gross profit
$0
$0
Selling, general and administrative
$1.26M
$1.9M
Research and development
$373K
$275K
Total operating expenses
$1.74M
$8.57M
Operating income
-$1.74M
-$8.57M
Interest expense
-$8.84M
-$100K
Income before taxes
-$11.18M
-$7.45M
Income taxes
-$23K
-$23K
Net income
-$11.16M
-$6.59M
Net income attributable to common shareholders
-$11.15M
-$6.58M
EBITDA
-$1.61M
-$2.2M
Basic earnings per share
-$68.30
-$53.70
Diluted earnings per share
-$68.30
-$53.70
Recent news
Company coverage with links to the original publishers.
Nexentis Technologies' subsidiary MitoCareX Bio Ltd. announced the appointment of Prof. Dan T. Major to its Scientific Advisory Board to strengthen its computational drug discovery capabilities. Prof. Major, a computational chemistry expert from Bar-Ilan University, will advise on in silico drug-discovery approaches and computational methods to support MitoCareX's expansion of internal scientific capabilities and prioritization of discovery programs.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.